Incyte Corp. buy marge
Start price
17.11.16
/
50%
€95.52
Target price
18.09.17
€135.30
Performance (%)
12.51%
End price
18.09.17
€107.47
Summary
This prediction ended on 18.09.17 with a price of €107.47. The prediction had a final performance of 12.51%. marge has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Incyte Corp. | 2.405% | 2.405% | -16.849% | -26.356% |
iShares Core DAX® | 0.476% | -0.039% | 13.342% | 17.330% |
iShares Nasdaq 100 | 1.290% | 0.504% | 40.099% | 50.534% |
iShares Nikkei 225® | 1.300% | -2.135% | 19.861% | 4.937% |
iShares S&P 500 | 0.829% | 0.193% | 29.756% | 43.432% |
Comments by marge for this prediction
In the thread Incyte Corp. diskutieren
marge stimmt der Buy-Einschätzung von datca zu: siehe Beschreibung
marge stimmt am 17.11.2016 der Buy-Einschätzung von datca mit dem Kursziel 120$ zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
(Laufzeit überschritten)